Biblio

Author Title [ Type

] Year

Filters: Author is Doorduijn, Jeanette K [Clear All Filters]

Journal Article

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, de Graauw NC van der, Schouten HC, Bilgin YM, et al. Rituximab-PECC induction followed by Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019.

Ferreri AJM, Doorduijn JK, Re A, Cabras MGiuseppina, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8(2):e110-e121.

Doorduijn JK, Kluin-Nelemans HC. Management of mantle cell lymphoma in the elderly patient. Clin Interv Aging. 2013;8:1229-1236.

Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJosee, Böhmer LH, Minnema MC, MacKenzie MA, Kooij Rvan Marwij, de Jongh E, Snijders TJF, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020.